Remdesivir Plus Dexamethasone Reduces Mortality Risk In Patients With COVID-19, Study Suggests

Infectious Disease Advisor (11/15, Basilio) reported, “Compared with dexamethasone alone, remdesivir plus dexamethasone is associated with reduced 14- and 28-day mortality rates in patients hospitalized with COVID-19 regardless of baseline respiratory support, according to study results.” The findings were published in Clinical Infectious Diseases.